Clay Siegall is a pharmaceutical magnate from Seattle, Washington. He is most well-known for being the founder and the chief executive officer of Seattle Genetics. The company was founded by Clay Siegall in 1988, and it focuses on creating pharmaceutical drugs that would treat a variety of diseases, including cancer. From its humble beginnings, Seattle Genetics have now grown to be valued at $10 billion, and the number of employees working at the company is now estimated to be at 900. Seattle Genetics, under the leadership of Clay Siegall, has been named to be the largest biotech company in the state of Washington, and they are looking forward to become one of the largest pharmaceutical and technological companies in the United States in the near future. Seattle Genetics has been investing in research and marketing, aiming to add an additional 200 employees to help them out.
Seattle Genetics is known for their flagship drug, Adcetris. It treats a disease known as Hodgkin lymphoma, which is a fatal lymph system cancer that can spread to other body systems. Aside from Adcetris, Clay Siegall is also stating that the company has an extensive list of medicines to be launched sometime in the future, and these medicines can treat a lot of diseases. For now, they are undergoing strict testing in order to become 100% effective once they are introduced into the market. Clay Siegall is also shifting the company’s focus onto international markets, opening up a satellite office in Switzerland to prepare for an expansion in the future.
Clay Siegall is vital for the growth of Seattle Genetics. He is responsible for establishing a name for the company, and his skills in the field of marketing resulted in their steep growth. Their sales have tripled in just two years, and their stock market prices have grown from $20 per share to over $66 per share in the present. According to the experts, if the current trend continues, the value of Seattle Genetics would surely hit the roof. For now, they have four medicines that will be introduced to the public one at a time, which would help cure different kinds of cancer. The first one is Adcetris, which has been discussed earlier that will treat Hodgkin lymphoma; next is medicine number 33A, which will be used to treat myeloid leukemia; the third one is codenamed 22ME, which will be used to treat bladder cancer; and last but not the least is LIV1, which will be used to treat breast cancer.